The National Center for Cardiovascular Diseases, the Chinese Medical Doctor Association (CMDA), and other organizations have released the revised “Clinical Practice Guidelines for Hypertension in China.” The updated guidelines adjust the diagnostic criteria for hypertension and provide detailed evidence-based recommendations for treating the disease, including both primary and secondary hypertension.<\/p>\n\n\n\n
Diagnostic Criteria and Patient Classification<\/strong>
The new guidelines recommend lowering the diagnostic threshold for adult hypertension in China from systolic blood pressure (SBP) \u2265 140 mmHg and\/or diastolic blood pressure (DBP) \u2265 90 mmHg to SBP \u2265 130 mmHg and\/or DBP \u2265 80 mmHg. Adult hypertensive patients are divided into two grades based on blood pressure levels: Grade 1 (SBP 130-139 mmHg and\/or DBP 80-89 mmHg) and Grade 2 (SBP \u2265 140 mmHg and\/or DBP \u2265 90 mmHg). The guidelines note that under the same treatment mode, higher pre-treatment levels of SBP or DBP correlate with a greater range of blood pressure reduction and a higher reduction in cardiovascular event risk. Therefore, the blood pressure classification of patients with SBP\/DBP \u2265 140\/90 mmHg before treatment may not be considered when determining the type, dose, or combination of antihypertensive drugs and other treatment strategies. This grading method simplifies the cardiovascular disease risk stratification for patients.<\/p>\n\n\n\n